C ORD , ▁to ▁examine ▁ros ig lit az one ▁and ▁card i ov asc ular ▁events . ▁Two ▁G SK ▁meta - anal ys es ▁in ▁ 2 0 0 5 , ▁and ▁ 2 0 0 6 , ▁showed ▁an ▁increased ▁risk ▁of ▁card i ov asc ular ▁problems ▁with ▁ros ig lit az one ; ▁the ▁information ▁was ▁passed ▁to ▁the ▁F DA ▁and ▁posted ▁on ▁the ▁company ▁website , ▁but ▁not ▁otherwise ▁published . ▁By ▁December ▁ 2 0 0 6 , ▁ros ig lit az one ▁had ▁become ▁the ▁top - s elling ▁di ab etes ▁drug , ▁with ▁annual ▁sales ▁of ▁US $ 3 . 3 b ill ion . ▁ ▁In ▁June ▁ 2 0 0 7 , ▁The ▁New ▁England ▁Journal ▁of ▁Medicine ▁published ▁a ▁meta - analysis ▁that ▁associated ▁the ▁drug ▁with ▁an ▁increased ▁risk ▁of ▁heart ▁attack . ▁G SK ▁had ▁reported ly ▁tried ▁to ▁persu ade ▁one ▁of ▁the ▁authors , ▁Steven ▁N issen , ▁not ▁to ▁publish ▁it , ▁after ▁receiving ▁an ▁advance ▁copy ▁from ▁one ▁of ▁the ▁journal ' s ▁peer ▁review ers , ▁a ▁G SK ▁consult ant . ▁In ▁July ▁ 2 0 0 7 , ▁F DA ▁scient ists ▁suggested ▁that ▁ros ig lit az one ▁had ▁caused ▁ 8 3 , 0 0 0 ▁excess ▁heart ▁attacks ▁between ▁ 1 9 9 9 , ▁and ▁ 2 0 0 7 . ▁The ▁F DA ▁placed ▁restrictions ▁on ▁the ▁drug , ▁including ▁adding ▁a ▁box ed ▁warning